A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
A phase 3 trial of Etoposide, Carboplatin and Cisplatin in small-cell lung cancer, run by EpicentRx, Inc., active and no longer recruiting.
Overview
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05566041 by EpicentRx, Inc., with 292 participants enrolled, started 2022-08-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: RRx-001 + eLOOP Device and Cisplatin/carboplatin plus etoposide.
Similar pages
not linked directly; found by shared links- TrialRRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
- TrialPembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Shares Etoposide, Cisplatin, Carboplatin, Small-cell lung cancer and the tag pipeline.
- TrialA Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
Shares Etoposide, Cisplatin, Carboplatin and the tag pipeline.
- TrialPharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
Shares Etoposide, Small-cell lung cancer and the tag pipeline.
- TrialA Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Shares EpicentRx and the tag pipeline.
- TrialStudy of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
Shares Etoposide, Carboplatin, Small-cell lung cancer and the tag pipeline.
- TrialStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Shares Etoposide, Cisplatin, Carboplatin and the tag pipeline.
- TrialA Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
Shares Cisplatin, Carboplatin and the tag pipeline.